Physician profile
Sameh Toma
NPI 1962461517
$864.54
in general payments reported to CMS, 2019-2025
13 companies · $147 in 2025
The $147 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $101 · 2021: $147 · 2022: $142 · 2023: $46.36 · 2024: $134 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $326.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $396.02 | 2019-2025 | Menopur |
| Emd Serono, INC. | $118.78 | 2019-2025 | |
| Coopersurgical, INC. | $58.17 | 2022-2023 | Stripper |
| Novo Nordisk INC | $52.46 | 2024-2025 | Wegovy |
| Sumitomo Pharma America, INC. | $46.45 | 2024-2025 | Myfembree |
| Myovant Sciences INC. | $41.06 | 2021-2022 | |
| Organon LLC | $30.38 | 2021-2022 | |
| Astellas Pharma US INC | $30.27 | 2023-2024 | Veozah, Myrbetriq |
| Galen US INC | $25.40 | 2019 | |
| Abbvie INC. | $20.68 | 2019 | |
| Pfizer INC. | $17.84 | 2021 | |
| Merck Sharp & Dohme LLC | $15.45 | 2021 | |
| Meditrina | $11.58 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameh Toma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.